Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

Proposed USPTO Fee Changes Will Make It Much More Expensive to Patent and to Challenge Patents on Th

Proposed USPTO Fee Changes Will Make It Much More Expensive to Patent and to Challenge Patents on Therapeutics. You Have an Opportunity to Comment… | Insights & Resources | Goodwin

Proposed USPTO Fee Changes Will Make It Much More Expensive to Patent and to Challenge Patents on Therapeutics. You Have an Opportunity to Comment…

Related Content

FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars

Accord BioPharma, Inc. Announces FDA Approval of HERCESSI (trastuzumab-strf)

PTAB Issues Final Written Decisions Finding Claims of Recombinant Lentiviral Vector Patents Valid

FDA Issues Final Rule on Regulation of Laboratory Developed Tests

Biosimilar Approval Updates in Europe and China

GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech for Infringing mRNA Vaccine Patents

Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR

Alvotech Announces Positive Topline Results From Confirmatory Clinical Study for its Proposed Golimumab Biosimilar

Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Amid Continued Growth in the United Kingdom, Goodwin Relocates London Office to Iconic Paternoster Square

Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Sound Bioventures joins £19 Million Financing of Theolytics

PowerUp 4 - Omer Tene (Spotify)

Goodwin is Number One in the Q1 2024 League Table Rankings

Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval

Life Sciences